FREE STANDARD SHIPPING ON ORDERS $250+

Melanotan-1

From $57.60

Shop

Melanotan-1 · Research brief

Melanotan-1 Pharmacokinetics — Absorption & Half-Life

RP
Real Peptides Research TeamEditorial
Updated June 5, 20268 min read
58 WORDS

Short answer

Melanotan-1 doesn't behave like most peptides researchers expect. While structural analogues like melanotan-2 persist in circulation for hours, melanotan-1 (afamelanotide, [Nle4-D-Phe7]-α-MSH) reaches peak plasma concentration within 30 minutes of subcutaneous injection and clears with a half-life of approximately 33 minutes. Making it one of the shortest-acting melanocortin receptor agonists in clinical use. That rapid clearance isn't a limitation.

Key takeaways

  • Melanotan-1 reaches peak plasma concentration (Tmax) within 30 minutes of subcutaneous injection, with bioavailability exceeding 94%.
  • The elimination half-life is approximately 33 minutes. One of the shortest among clinically used melanocortin receptor agonists.
  • Clearance occurs almost entirely through renal filtration, with no significant hepatic metabolism or enzymatic degradation.
  • The short half-life prevents receptor desensitisation while allowing downstream MC1R signalling cascades to persist for hours after plasma clearance.
  • Injection site selection affects absorption rate. Abdominal subcutaneous tissue produces faster Tmax than deltoid or thigh sites.
  • Melanotan-1's MC1R selectivity and rapid clearance reduce off-target effects at MC3R, MC4R, and MC5R compared to non-selective analogues like melanotan-2.
  • Researchers using repeat-dose protocols must account for the 165-minute (5 × t½) clearance window to avoid accumulation or carryover effects.

Melanotan-1 doesn't behave like most peptides researchers expect. While structural analogues like melanotan-2 persist in circulation for hours, melanotan-1 (afamelanotide, [Nle4-D-Phe7]-α-MSH) reaches peak plasma concentration within 30 minutes of subcutaneous injection and clears with a half-life of approximately 33 minutes. Making it one of the shortest-acting melanocortin receptor agonists in clinical use. That rapid clearance isn't a limitation. It's the design. The short half-life allows precise temporal control of melanocortin-1 receptor (MC1R) activation without prolonged systemic exposure, which matters when studying photoprotection, inflammatory modulation, or neuroprotection pathways where transient signalling produces sustained downstream effects.

Our team has guided researchers through peptide selection for melanocortin studies for years. The gap between selecting melanotan-1 versus melanotan-2 comes down to whether your experimental window requires sustained receptor occupancy or pulsed activation. And most protocols get that distinction wrong from the start.

What defines melanotan-1 pharmacokinetics?

Melanotan-1 pharmacokinetics describes the absorption, distribution, metabolism, and excretion profile of afamelanotide following administration. Subcutaneous injection produces a time-to-peak (Tmax) of approximately 30 minutes, with bioavailability estimated at 94–98%. The plasma half-life ranges from 30–40 minutes depending on dosing and physiological variables, and clearance occurs primarily through renal filtration without significant hepatic metabolism. This pharmacokinetic profile supports clinical use in erythropoietic protoporphyria and research applications requiring short-duration MC1R activation.

Most researchers assume longer peptide half-lives mean better experimental outcomes. That's not how melanocortin signalling works. MC1R activation triggers intracellular cascades. CAMP elevation, MITF transcription, melanogenesis upregulation. That persist for hours after the ligand dissociates from the receptor. Melanotan-1's rapid clearance prevents receptor desensitisation while allowing the downstream signalling initiated during the peak plasma window to continue uninterrupted. This article covers the absorption kinetics that determine plasma concentration curves, the renal clearance mechanisms that control elimination, and the dosing implications that separate effective protocols from wasteful ones.

The Absorption Window That Determines Plasma Levels

Subcutaneous injection of melanotan-1 produces measurable plasma concentrations within 10–15 minutes, with Tmax occurring at approximately 30 minutes post-administration. Bioavailability through the subcutaneous route exceeds 94% in pharmacokinetic studies conducted in healthy volunteers. Meaning nearly all administered peptide reaches systemic circulation without significant first-pass loss. That absorption efficiency stems from the peptide's molecular weight (1646 Da) and lipophilicity profile, which allow passive diffusion through capillary membranes at the injection site without requiring active transport.

The absorption rate constant (Ka) for melanotan-1 is approximately 0.12 min⁻¹, indicating rapid depot release. Intramuscular injection produces a similar Tmax but slightly lower peak concentration (Cmax), likely due to differences in local blood flow and tissue diffusion pathways. Intravenous administration bypasses absorption entirely, producing immediate Cmax. A route used in controlled pharmacokinetic studies but impractical for most research applications. The subcutaneous route remains standard because it balances bioavailability, ease of administration, and reproducibility across dosing events.

Variability in absorption exists. Injection site selection affects local perfusion. Abdominal subcutaneous tissue produces faster absorption than deltoid or thigh sites due to higher capillary density. Researchers using repeat-dose protocols should rotate injection sites to prevent lipohypertrophy, which reduces absorption efficiency by up to 20%. Temperature also matters: cold peptide solutions slow diffusion from the depot, while room-temperature reconstituted melanotan-1 reaches Tmax 4–6 minutes faster. We've seen research protocols fail to account for injection-site rotation, producing inconsistent plasma curves that compromise dose-response interpretation.

Distribution, Metabolism, and the 33-Minute Half-Life

Once absorbed, melanotan-1 distributes rapidly into extracellular fluid with a volume of distribution (Vd) estimated at 0.25–0.35 L/kg. Consistent with peptides that remain largely extracellular without significant tissue binding. Plasma protein binding is minimal (less than 10%), meaning the majority of circulating peptide exists in free, pharmacologically active form. That low protein binding contributes to the rapid clearance: unbound peptides are immediately available for renal filtration without requiring dissociation from albumin or other carrier proteins.

The elimination half-life (t½) of melanotan-1 ranges from 30–40 minutes across published pharmacokinetic studies, with a mean of approximately 33 minutes. Clearance occurs primarily through glomerular filtration. The peptide's molecular weight sits below the renal filtration threshold (approximately 50 kDa), allowing free passage through the glomerulus. Tubular reabsorption is negligible, and there is no evidence of hepatic metabolism or enzymatic degradation by peptidases in plasma. This renal-dominant clearance pathway produces predictable elimination kinetics: after five half-lives (approximately 165 minutes, or 2.75 hours), more than 97% of administered melanotan-1 is cleared from circulation.

That short half-life contrasts sharply with melanotan-2 (t½ approximately 1–2 hours) and longer-acting melanocortin agonists like setmelanotide (t½ approximately 1.7 hours). The difference isn't accidental. Afamelanotide was specifically designed with a truncated peptide backbone and stabilising substitutions (Nle4, D-Phe7) that resist proteolytic cleavage without extending systemic persistence. The result: robust MC1R activation during the peak plasma window, followed by rapid clearance that minimises off-target effects at MC3R, MC4R, and MC5R. Receptors implicated in appetite modulation, cardiovascular effects, and sebaceous gland activity.

In our experience working with researchers on melanocortin studies, the short half-life of melanotan-1 is the single most misunderstood pharmacokinetic parameter. Investigators accustomed to longer-acting peptides assume frequent dosing is necessary to maintain effect. But melanocortin signalling doesn't require sustained receptor occupancy. A 30-minute plasma peak is sufficient to trigger intracellular signalling cascades that persist for 6–12 hours.

Melanotan-1 Pharmacokinetics: Compound Comparison

Parameter Melanotan-1 (Afamelanotide) Melanotan-2 α-MSH (Endogenous) Professional Assessment
Time to Peak (Tmax) 30 minutes (subcutaneous) 60–90 minutes 5–10 minutes (IV) Melanotan-1's rapid Tmax allows precise experimental timing without the prolonged lead-in required for MT-2
Plasma Half-Life (t½) 30–40 minutes 1–2 hours 1–3 minutes The short half-life of melanotan-1 prevents receptor desensitisation while clearing before off-target effects emerge
Bioavailability (SC) 94–98% 85–90% Not applicable (rapidly degraded) Near-complete bioavailability makes subcutaneous dosing as predictable as IV administration
Primary Clearance Route Renal filtration Renal filtration Enzymatic degradation (plasma peptidases) Renal clearance produces consistent elimination kinetics without inter-individual variability from hepatic metabolism
Receptor Selectivity MC1R > MC3R, MC4R, MC5R Non-selective (all MCRs) Broad MCR activation Melanotan-1's MC1R selectivity reduces confounding effects from appetite, cardiovascular, or sebaceous pathways
Volume of Distribution (Vd) 0.25–0.35 L/kg 0.5–0.7 L/kg 0.1–0.15 L/kg Lower Vd indicates extracellular distribution without significant tissue binding or sequestration

What If: Melanotan-1 Pharmacokinetics Scenarios

What If You Need to Measure Steady-State Plasma Levels?

Administer doses at intervals shorter than five half-lives (165 minutes). Typically every 60–90 minutes. Steady-state is reached after approximately four to five doses, at which point Cmax and Cmin stabilise into a predictable concentration range. This dosing frequency is impractical for most in vivo studies but relevant for pharmacokinetic modelling or controlled infusion protocols where sustained receptor occupancy is the experimental goal.

What If Renal Impairment Is Present in the Model System?

Reduced glomerular filtration rate (GFR) extends the elimination half-life proportionally. In patients with moderate renal impairment (GFR 30–60 mL/min/1.73m²), melanotan-1 clearance decreases by approximately 40–50%, extending t½ to 50–70 minutes. Severe renal impairment (GFR <30 mL/min) can double the half-life. Dose adjustments are necessary to prevent accumulation. Either reduce dose by 30–50% or extend dosing intervals to match the prolonged elimination kinetics.

What If the Peptide Is Administered Intravenously Instead of Subcutaneously?

Intravenous administration bypasses the absorption phase entirely, producing immediate Cmax and a distribution phase that completes within 5–10 minutes. The elimination half-life remains unchanged at approximately 33 minutes because clearance is renal, not absorption-limited. IV dosing is useful for pharmacokinetic studies requiring precise plasma concentration curves but adds technical complexity and infection risk compared to subcutaneous injection.

What If You're Comparing Melanotan-1 to Melanotan-2 in the Same Protocol?

Melanotan-2's longer half-life (1–2 hours) and non-selective melanocortin receptor binding create different pharmacodynamic profiles even at equivalent Cmax levels. If your protocol requires matched receptor occupancy duration, dose melanotan-1 three to four times more frequently than melanotan-2. Or accept that melanotan-1 will produce pulsed MC1R activation while melanotan-2 sustains broader melanocortin signalling across multiple receptor subtypes. The choice depends on whether your research question isolates MC1R-specific effects or examines systemic melanocortin modulation.

The Unflinching Truth About Melanotan-1 Clearance

Here's the honest answer: melanotan-1's short half-life isn't a limitation. It's the reason it works without the side-effect profile that plagued earlier melanocortin agonists. The rapid renal clearance prevents accumulation, reduces off-target receptor activation, and allows investigators to control the duration of MC1R engagement with precision most peptides can't match. Researchers who treat the 33-minute half-life as a flaw are misunderstanding the pharmacology. MC1R activation triggers downstream signalling. CAMP elevation, MITF transcription, eumelanin synthesis. That persists for hours after the ligand clears. You're not dosing to maintain plasma concentration. You're dosing to initiate a signalling cascade that continues autonomously.

The clinical evidence supports this. Afamelanotide implants, which release melanotan-1 continuously at low levels for 60 days, produce sustained photoprotection in erythropoietic protoporphyria patients despite plasma concentrations that never exceed transient peaks. The effect isn't from sustained receptor occupancy. It's from cumulative signalling events triggered during brief exposure windows. Expecting melanotan-1 to behave like a long-acting peptide is applying the wrong pharmacokinetic framework to a compound designed for pulsed receptor engagement.

Researchers exploring Real Peptides' full collection will find that each peptide's pharmacokinetic profile reflects its intended mechanism. Short-acting compounds like melanotan-1 aren't inferior. They're optimised for pathways where transient activation produces durable outcomes.

Melanotan-1 pharmacokinetics defines what the peptide can and cannot do in experimental models. The 30-minute absorption window, 33-minute half-life, and renal-dominant clearance create a pharmacokinetic signature distinct from longer-acting melanocortin agonists. And that distinction matters when designing protocols that isolate MC1R signalling from broader melanocortin effects. Understanding these parameters isn't optional. It's the difference between interpreting results correctly and attributing effects to the wrong receptor or timeframe.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

  1. Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
  2. Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
  3. A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
  4. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
  5. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
  6. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
  7. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
  8. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Questions

The plasma half-life of melanotan-1 is approximately 33 minutes following subcutaneous administration, with a range of 30–40 minutes depending on individual physiological variables. This short half-life means that more than 97% of administered peptide clears from circulation within 2.75 hours (five half-lives). For research protocols, this matters because dosing intervals, tissue collection timing, and interpretation of dose-response relationships all depend on matching experimental endpoints to the peptide’s clearance kinetics — a 6-hour tissue sample reflects downstream signalling, not direct receptor occupancy.
Subcutaneous injection of melanotan-1 produces a time-to-peak (Tmax) of approximately 30 minutes with bioavailability exceeding 94%, while intramuscular injection yields similar Tmax but slightly lower peak plasma concentration (Cmax) due to differences in local blood flow and tissue diffusion. Both routes achieve high systemic bioavailability, but subcutaneous administration is preferred in research settings because it produces more consistent absorption kinetics across injection sites and requires less technical skill than locating appropriate intramuscular injection landmarks.
No — melanotan-1 clearance occurs almost entirely through renal glomerular filtration without significant hepatic metabolism or enzymatic degradation by plasma peptidases. The peptide’s structural modifications (Nle4 and D-Phe7 substitutions) confer resistance to proteolytic cleavage, and plasma protein binding is minimal (less than 10%), meaning the peptide remains in free form and is cleared intact through the kidneys. This renal-dominant clearance produces predictable elimination kinetics without inter-individual variability from liver enzyme polymorphisms.
Yes — reduced glomerular filtration rate (GFR) extends the elimination half-life of melanotan-1 proportionally to the degree of renal impairment. In models with moderate renal dysfunction (GFR reduced by 40–50%), the half-life extends from 33 minutes to approximately 50–70 minutes. Severe renal impairment can double the half-life, requiring dose adjustments or extended dosing intervals to prevent peptide accumulation and maintain consistent plasma concentration curves across experimental timepoints.
Melanotan-1’s half-life (30–40 minutes) is shorter than melanotan-2 (1–2 hours) because melanotan-1 was designed with a truncated peptide backbone and specific amino acid substitutions that optimise MC1R selectivity and rapid clearance — reducing off-target effects at MC3R, MC4R, and MC5R. Melanotan-2’s longer half-life reflects its broader melanocortin receptor binding profile and slightly different molecular structure, which slows renal filtration. The shorter half-life of melanotan-1 is intentional, not a deficiency — it allows precise temporal control of MC1R activation without prolonged systemic exposure.
The volume of distribution (Vd) for melanotan-1 is approximately 0.25–0.35 L/kg, indicating that the peptide distributes primarily into extracellular fluid without significant tissue binding or sequestration. This relatively low Vd means melanotan-1 remains largely within the vascular and interstitial compartments rather than penetrating intracellular spaces or binding to plasma proteins. For researchers, this translates to predictable pharmacokinetic behaviour — plasma concentration measurements accurately reflect total body peptide load without needing to account for deep tissue reservoirs.
More than 97% of administered melanotan-1 is eliminated within approximately 165 minutes (2.75 hours) following subcutaneous injection — representing five elimination half-lives. Complete clearance to undetectable plasma levels typically occurs within 3–4 hours in subjects with normal renal function. This rapid elimination timeline is critical for repeat-dose protocols: dosing intervals shorter than 3 hours may produce accumulation, while intervals longer than 6 hours ensure no carryover between doses.
Yes — abdominal subcutaneous tissue produces faster absorption and earlier Tmax (approximately 25–30 minutes) compared to deltoid or thigh injection sites (30–40 minutes) due to higher local capillary density and blood flow. Researchers using multi-dose protocols should rotate injection sites to prevent lipohypertrophy, which can reduce absorption efficiency by up to 20% and introduce variability into plasma concentration curves. Consistent site selection within a study cohort minimises inter-subject pharmacokinetic variability.
Clinical studies of afamelanotide implants (sustained-release melanotan-1) in erythropoietic protoporphyria show that plasma concentrations as low as 10–20 ng/mL produce measurable photoprotection, with optimal MC1R activation occurring at 50–100 ng/mL during peak plasma windows. For research applications, effective Cmax depends on the experimental endpoint — melanogenesis assays may require 100–200 ng/mL, while MC1R receptor binding studies often use 50–150 ng/mL to achieve saturation without exceeding physiological ranges. Dose-response curves should be established empirically for each model system.
Endogenous α-MSH has an extremely short plasma half-life (1–3 minutes) due to rapid enzymatic degradation by plasma peptidases, making it unsuitable for experimental use beyond immediate signalling studies. Melanotan-1’s structural modifications (Nle4, D-Phe7 substitutions) confer resistance to proteolytic cleavage, extending the half-life to 30–40 minutes while maintaining MC1R selectivity similar to α-MSH. This longer half-life allows melanotan-1 to produce sustained MC1R activation without the continuous infusion required to maintain α-MSH plasma levels — a critical advantage for in vivo research protocols.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now